Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AtriCure stock | 40.7

Own AtriCure stock in just a few minutes.


Fact checked

AtriCure, Inc is a medical instruments & supplies business based in the US. AtriCure shares (ATRC) are listed on the NASDAQ and all prices are listed in US Dollars. AtriCure employs 730 staff and has a trailing 12-month revenue of around USD$212 million.

How to buy shares in AtriCure

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AtriCure. Find the stock by name or ticker symbol: ATRC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AtriCure reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$40.7, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AtriCure, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AtriCure. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted AtriCure's share price?

Since the stock market crash in March caused by coronavirus, AtriCure's share price has had significant positive movement.

Its last market close was USD$40.7, which is 3.17% up on its pre-crash value of USD$39.41 and 75.70% up on the lowest point reached during the March crash when the shares fell as low as USD$23.165.

If you had bought USD$1,000 worth of AtriCure shares at the start of February 2020, those shares would have been worth USD$679.60 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,052.91.

AtriCure share price

Use our graph to track the performance of ATRC stocks over time.

AtriCure shares at a glance

Information last updated 2020-10-20.
Latest market close USD$40.7
52-week range USD$23.165 - USD$51.76
50-day moving average USD$40.738
200-day moving average USD$42.8283
Wall St. target price USD$55.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.565

Buy AtriCure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AtriCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AtriCure price performance over time

Historical closes compared with the close of $40.7 from 2020-11-16

1 week (2020-11-20) -4.15%
1 month (2020-10-30) 17.77%
3 months (2020-08-28) -4.28%
6 months (2020-05-29) -14.87%
1 year (2019-11-29) 36.81%
2 years (2018-11-29) 22.59%
3 years (2017-11-29) 121.44%
5 years (2015-11-27) 81.62%

AtriCure financials

Revenue TTM USD$212 million
Gross profit TTM USD$170.3 million
Return on assets TTM -5.83%
Return on equity TTM -15.22%
Profit margin -23.64%
Book value $9.276
Market capitalisation USD$1.8 billion

TTM: trailing 12 months

Shorting AtriCure shares

There are currently 2.2 million AtriCure shares held short by investors – that's known as AtriCure's "short interest". This figure is 18.5% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting AtriCure shares can be evaluated.

AtriCure's "short interest ratio" (SIR)

AtriCure's "short interest ratio" (SIR) is the quantity of AtriCure shares currently shorted divided by the average quantity of AtriCure shares traded daily (recently around 351686.14173228). AtriCure's SIR currently stands at 6.35. In other words for every 100,000 AtriCure shares traded daily on the market, roughly 6350 shares are currently held short.

However AtriCure's short interest can also be evaluated against the total number of AtriCure shares, or, against the total number of tradable AtriCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AtriCure's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 AtriCure shares in existence, roughly 50 shares are currently held short) or 0.0595% of the tradable shares (for every 100,000 tradable AtriCure shares, roughly 60 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AtriCure.

Find out more about how you can short AtriCure stock.

AtriCure share dividends

We're not expecting AtriCure to pay a dividend over the next 12 months.

AtriCure share price volatility

Over the last 12 months, AtriCure's shares have ranged in value from as little as $23.165 up to $51.76. A popular way to gauge a stock's volatility is its "beta".

ATRC.US volatility(beta: 0.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AtriCure's is 0.717. This would suggest that AtriCure's shares are less volatile than average (for this exchange).

AtriCure overview

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site